OCTO Home
The Oncology Clinical Trials Office (OCTO) is concerned with the practical application of high-quality clinical research into innovative and effective cancer therapies particularly in the field of gastrointestinal cancer. OCTO's key aims are to improve both survival rates and the quality of life of cancer patients by contributing to the evidence-base that will underpin cancer services now and in the future; and to bring about major and continuing improvements in the quality of practice in clinical research. These aims will be achieved in partnership with academic-led research communities, with industry and with patients and their carers. We aspire to put OCTO on a par with the best in the world, and to establish it as a national and international leader in its approach to the integration of research, treatment and care for cancer patients. OCTO is part of the Clinical Pharmacology Department of Oxford University.
OCTRU
The Oxford Clinical Trials Research Unit (OCTRU) integrates the work of OCTO and CSM (Centre for Statistics in Medicine). To indicate interest in their work, please send us a completed Background Information Form.
BREAKING NEWS - QUASAR 2
Further to the recent press release from Roche (see attached) re: the preliminary results of the C-08 trial of Avastin in the adjuvant treatment of colon cancer, we would like to confirm to our research community that we do not feel these results impact upon the continuing validity of or rationale for the QUASAR2 study. Indeed we believe that this result re-emphasises the importance of the QUASAR2 study. At the present time the results from the C-08 trial have not been released and are due to be presented at the ASCO meeting next month. However the trial tested the benefit of Avastin when added to a 5FU/oxaliplatin regime, which is significantly different to the question being asked in the QUASAR2 study, where we are assessing the effect of Avastin when added to single agent capecitabine. We are pleased to report that recruitment into QUASAR2 is going very well with today’s recruitment figure standing at 1459 of a required total of 2240. We thank you wholeheartedly for your continuing support.
Rachel Midgley and David Kerr
BREAKING NEWS - COG
We are very pleased to tell you that
the COG Trial is now open to recruitment!
Congratulations to
Mount Vernon Cancer Centre
for being our first site and for recruiting our first two patients.
We look forward to welcoming all of our participating sites on board and we want to say a big Thank You for your continued efforts that are helping us get COG up and running.
Please do not hesitate to get in touch with any questions, and please let us know what we can do to speed up your site opening process.
BREAKING NEWS - SCOT
The number of CT scans mandated by the protocol is currently under review.
Click here for further details about the trial.
